Literature DB >> 23623236

Variations in institutional review board reviews of a multi-center, Emergency Department (ED)-based genetic research protocol.

David C Lee1, David A Peak, Jeffrey S Jones, Robert M Domeier, Phyllis L Hendry, Niels K Rathlev, Robert A Swor, Samuel A McLean.   

Abstract

INTRODUCTION: In the United States, institutional review boards (IRBs) oversee the scientific, ethical, and regulatory aspects of research conducted on human subjects. Institutional variations in the interpretation and application of federal and local regulations concerning genetic testing can have significant impact on the implementation of such studies.
OBJECTIVE: We assessed variability in IRB review of a multi-center Emergency Department-based study examining genotypic and phenotypic predictors of pain and psychological outcomes after minor motor vehicle collision (Project CRASH). This is one of the first multi-center genetic research protocols based solely in the Emergency Department (ED).
METHODS: We performed an observational study of sites participating in Project CRASH. We collected IRB information and correspondence from each site. We collected data that included information regarding institution demographics, original IRB application characteristics, subsequent IRB correspondence, and time interval between submission and approval. Descriptive statistics were used in analysis.
RESULTS: All sites that initially agreed to participate in Project CRASH also participated in this study (n = 7). The time interval in receiving IRB approval varied between 20-760 days (median 105, IQR 21-225). One site appeared to be an outlier (760 days). The most commonly requested changes were changes to the consent form.
CONCLUSION: Institutional interpretation of regulations regarding our ED-based genetic study was highly variable. Although the majority of our results are consistent with other similar published studies, the mean time interval for approval for this genetic study is far greater than other reported studies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23623236      PMCID: PMC3926443          DOI: 10.1016/j.ajem.2013.03.003

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  5 in total

1.  Variation in institutional review board responses to a standard protocol for a multicenter clinical trial.

Authors:  T O Stair; C R Reed; M S Radeos; G Koski; C A Camargo
Journal:  Acad Emerg Med       Date:  2001-06       Impact factor: 3.451

Review 2.  Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts.

Authors: 
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

3.  Variation in institutional review board responses to a standard, observational, pediatric research protocol.

Authors:  Jonathan Mansbach; Uchechi Acholonu; Sunday Clark; Carlos A Camargo
Journal:  Acad Emerg Med       Date:  2007-02-20       Impact factor: 3.451

4.  Problematic variation in local institutional review of a multicenter genetic epidemiology study.

Authors:  Rita McWilliams; Julie Hoover-Fong; Ada Hamosh; Suzanne Beck; Terri Beaty; Garry Cutting
Journal:  JAMA       Date:  2003-07-16       Impact factor: 56.272

5.  Variation among institutional review boards in evaluating the design of a multicenter randomized trial.

Authors:  A R Stark; J E Tyson; P L Hibberd
Journal:  J Perinatol       Date:  2009-10-01       Impact factor: 2.521

  5 in total
  2 in total

1.  Harmonization and streamlining of research oversight for pragmatic clinical trials.

Authors:  P Pearl O'Rourke; Judith Carrithers; Bray Patrick-Lake; Todd W Rice; Jeremy Corsmo; Raffaella Hart; Marc K Drezner; John D Lantos
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

2.  Fuzzy multi-objective medical service organization selection model considering limited resources and stochastic demand in emergency management.

Authors:  ShuJie Liao; Haiting Tu; Cheng Hu; Wulin Pan; Jianwu Xiong; Dongyang Yu; Lei Jing; Wei Pan
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.